1
|
Modh DH, Kulkarni VM. Anticancer Drug Discovery By Structure-Based Repositioning Approach. Mini Rev Med Chem 2024; 24:60-91. [PMID: 37165589 DOI: 10.2174/1389557523666230509123036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 03/07/2023] [Accepted: 03/28/2023] [Indexed: 05/12/2023]
Abstract
Despite the tremendous progress that has occurred in recent years in cell biology and oncology, in chemical, physical and computer sciences, the disease cancer has continued as the major cause of death globally. Research organizations, academic institutions and pharmaceutical companies invest huge amounts of money in the discovery and development of new anticancer drugs. Though much effort is continuing and whatever available approaches are being attempted, the success of bringing one effective drug into the market has been uncertain. To overcome problems associated with drug discovery, several approaches are being attempted. One such approach has been the use of known, approved and marketed drugs to screen these for new indications, which have gained considerable interest. This approach is known in different terms as "drug repositioning or drug repurposing." Drug repositioning refers to the structure modification of the active molecule by synthesis, in vitro/ in vivo screening and in silico computational applications where macromolecular structure-based drug design (SBDD) is employed. In this perspective, we aimed to focus on the application of repositioning or repurposing of essential drug moieties present in drugs that are already used for the treatment of some diseases such as diabetes, human immunodeficiency virus (HIV) infection and inflammation as anticancer agents. This review thus covers the available literature where molecular modeling of drugs/enzyme inhibitors through SBDD is reported for antidiabetics, anti-HIV and inflammatory diseases, which are structurally modified and screened for anticancer activity using respective cell lines.
Collapse
Affiliation(s)
- Dharti H Modh
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Erandwane, Pune, 411038, Maharashtra, India
| | - Vithal M Kulkarni
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Erandwane, Pune, 411038, Maharashtra, India
| |
Collapse
|
2
|
Renault J, Bouvry C, Cupif JF, Hurvois JP. Alkylation of N, N-Dibenzylaminoacetonitrile: From Five- to Seven-Membered Nitrogen-Containing Heterocyclic Systems. J Org Chem 2023; 88:3582-3598. [PMID: 36848662 DOI: 10.1021/acs.joc.2c02795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
The syntheses of several alkaloids and nitrogen-containing compounds including N-Boc-coniine (14b), pyrrolizidine (1), δ-coniceine (2), and pyrrolo[1,2a]azepine (3) are described. New C-C bonds in the α position relative to the nitrogen atom were formed by the alkylation of metalated α-aminonitriles 4 and 6a-c with alkyl iodides possessing the requisite size and functionality. In all of the reported cases, the pyrrolidine ring was formed in the aqueous medium through a favorable 5-exo-tet process involving a primary or a secondary amino group and a terminal δ-leaving group. Conversely, the azepane ring was efficiently formed in N,N-dimethylformamide (DMF), as the preferred aprotic solvent, through an unreported 7-exo-tet cyclization process involving a more nucleophilic sodium amide and a terminal mesylate borne by a saturated six carbon chain unit. In this way, we successfully synthesized pyrrolo[1,2a]azepane 3 and 2-propyl-azepane 14c in good yields from inexpensive and readily available materials without tedious separation methods.
Collapse
Affiliation(s)
- Jacques Renault
- Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques Rennes), UMR 6226, F-35000 Rennes, France
| | - Christelle Bouvry
- Comprehensive Cancer Center Eugène Marquis, Avenue de la Bataille Flandre-Dunkerque, 35000 Rennes, France
| | - Jean-François Cupif
- Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques Rennes), UMR 6226, F-35000 Rennes, France
| | - Jean-Pierre Hurvois
- Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques Rennes), UMR 6226, F-35000 Rennes, France
| |
Collapse
|
3
|
Modh DH, Modi SJ, Deokar H, Yadav S, Kulkarni VM. Fibroblast growth factor receptor (FGFR) inhibitors as anticancer agents: 3D-QSAR, molecular docking and dynamics simulation studies of 1, 6-naphthyridines and pyridopyrimidines. J Biomol Struct Dyn 2022; 41:3591-3606. [PMID: 35318898 DOI: 10.1080/07391102.2022.2053206] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Fibroblast growth factor receptor (FGFR) plays a vital role in tissue regeneration, angiogenesis, and embryogenesis. 3D-QSAR and molecular modeling methods are widely used for designing novel compounds for the determination of inhibitory activity against the biological target. In the present study, 3D-QSAR (CoMFA and CoMSIA) analysis was performed on 1, 6-naphthyridines, and pyridopyrimidines as potential FGFR inhibitors as anticancer agents. The best CoMFA and CoMSIA models were generated from test and training set derivatives with leave-one-out correlation coefficients (q2) 0.591 and 0.667, cross-validated correlation coefficients (r2cv) 0.584 and 0.652, conventional coefficients (r2ncv) 0.978 and 0.975 respectively. The developed models were validated by a test set of 12 compounds providing acceptable predictive correlation coefficient (r2pred) 0.61 and 0.68 for both models. The generated CoMFA and CoMSIA contour maps could be used to design novel 1, 6-naphthyridine analogs. Molecular docking studies indicated that compound 75 occupied the active site of the FGFR kinase interacting with Glu520 in the catalytic region, Asp630 in the DFG motif, and Met524 in the hinge region which compared with standard drug Ponatinib. The molecular dynamics simulation analysis revealed that the inhibitor 75 displayed binding stability in the active site of the FGFR4 by making two hydrogen bonds and one π-cation interaction. Collectively the outcome of the study suggested that the applications of ligand-based and structure-based approaches could be applied for the design of new FGFR4 inhibitors as anticancer agents.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Dharti H Modh
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra, India
| | - Siddharth J Modi
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra, India
| | - Hemant Deokar
- Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Savita Yadav
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra, India
| | - Vithal M Kulkarni
- Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra, India
| |
Collapse
|
4
|
Lavanya M, Lin C, Mao J, Thirumalai D, Aabaka SR, Yang X, Mao J, Huang Z, Zhao J. Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines. Top Curr Chem (Cham) 2021; 379:13. [PMID: 33624162 DOI: 10.1007/s41061-020-00314-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 11/12/2020] [Indexed: 12/29/2022]
Abstract
The burgeoning interest in synthesis and biological applications of 1,6-naphthyridines reflects the importance of 1,6-naphthyridines in the synthetic as well as medicinal chemistry fields. Specially, 1,6-naphthyridines are pharmacologically active, with variety of applications such as anticancer, anti-human immunodeficiency virus (HIV), anti-microbial, analgesic, anti-inflammatory and anti-oxidant activities. Although collective recent synthetic developments have paved a path to a wide range of functionalized 1,6-naphthyridines, a complete correlation of synthesis with biological activity remains elusive. The current review focuses on recent synthetic developments from the last decade and a thorough study of the anticancer activity of 1,6-naphthyridines on different cancer cell lines. Anticancer activity has been correlated to 1,6-naphthyridines using the literature on the structure-activity relationship (SAR) along with molecular modeling studies. Exceptionally, at the end of this review, the utility of 1,6-naphthyridines displaying activities other than anticancer has also been included as a glimmering extension.
Collapse
Affiliation(s)
- Mallu Lavanya
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China.,School of Chemistry and Chemical Engineering, Southwest Petroleum University, Chengdu, 610500, People's Republic of China
| | - Chong Lin
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China.
| | - Jincheng Mao
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China.
| | | | - Sreenath Reddy Aabaka
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| | - Xiaojiang Yang
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| | - Jinhua Mao
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| | - Zhiyu Huang
- School of Chemistry and Chemical Engineering, Southwest Petroleum University, Chengdu, 610500, People's Republic of China
| | - Jinzhou Zhao
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| |
Collapse
|
5
|
Kashid BB, Salunkhe PH, Dongare BB, More KR, Khedkar VM, Ghanwat AA. Synthesis of novel of 2, 5-disubstituted 1, 3, 4- oxadiazole derivatives and their in vitro anti-inflammatory, anti-oxidant evaluation, and molecular docking study. Bioorg Med Chem Lett 2020; 30:127136. [DOI: 10.1016/j.bmcl.2020.127136] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Revised: 03/17/2020] [Accepted: 03/20/2020] [Indexed: 02/06/2023]
|
6
|
Wang MS, Zhuo LS, Yang FP, Wang WJ, Huang W, Yang GF. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold. Eur J Med Chem 2020; 185:111803. [DOI: 10.1016/j.ejmech.2019.111803] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 10/02/2019] [Accepted: 10/19/2019] [Indexed: 12/16/2022]
|
7
|
Volynets G, Lukashov S, Borysenko I, Gryshchenko A, Starosyla S, Bdzhola V, Ruban T, Iatsyshyna A, Lukash L, Bilokin Y, Yarmoluk S. Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzimidazol-1-yl)-3-hydroxythiophene-2-carboxylic acid. MONATSHEFTE FUR CHEMIE 2019. [DOI: 10.1007/s00706-019-02493-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
8
|
Farrokhzadeh A, Akher FB, Olotu FA, Soliman MES, Van Heerden FR. Revealing the distinct mechanistic binding and activity of 5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazole enantiomers against FGFR1. Phys Chem Chem Phys 2019; 21:15120-15132. [DOI: 10.1039/c9cp02112d] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The concept of chirality has become prominent over the years, particularly with regards to the design of therapeutic molecules.
Collapse
Affiliation(s)
- Abdolkarim Farrokhzadeh
- Molecular Bio-Computation and Drug Design Laboratory
- School of Health Sciences
- University of KwaZulu-Natal
- Westville Campus
- Durban 4001
| | - Farideh Badichi Akher
- Molecular Bio-Computation and Drug Design Laboratory
- School of Health Sciences
- University of KwaZulu-Natal
- Westville Campus
- Durban 4001
| | - Fisayo A. Olotu
- Molecular Bio-Computation and Drug Design Laboratory
- School of Health Sciences
- University of KwaZulu-Natal
- Westville Campus
- Durban 4001
| | - Mahmoud E. S. Soliman
- Molecular Bio-Computation and Drug Design Laboratory
- School of Health Sciences
- University of KwaZulu-Natal
- Westville Campus
- Durban 4001
| | - Fanie R. Van Heerden
- School of Chemistry and Physics
- University of KwaZulu-Natal
- Pietermaritzburg 3209
- South Africa
| |
Collapse
|
9
|
Synthesis and photocytotoxic activity of [1,2,3]triazolo[4,5-h][1,6]naphthyridines and [1,3]oxazolo[5,4-h][1,6]naphthyridines. Eur J Med Chem 2018; 162:176-193. [PMID: 30445266 DOI: 10.1016/j.ejmech.2018.10.071] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 10/02/2018] [Accepted: 10/31/2018] [Indexed: 12/31/2022]
Abstract
[1,2,3]Triazolo[4,5-h][1,6]naphthyridines and [1,3]oxazolo[5,4-h][1,6]naphthyridines were synthesized with the aim to investigate their photocytotoxic activity. Upon irradiation, oxazolo-naphtapyridines induced light-dependent cell death at nanomolar/low micromolar concentrations (EC50 0.01-6.59 μM). The most photocytotoxic derivative showed very high selectivity and photocytotoxicity indexes (SI = 72-86, PTI>5000), along with a triplet excited state with exceptionally long lifetime (18.0 μs) and high molar absorptivity (29781 ± 180 M-1cm-1 at λmax 315 nm). The light-induced production of ROS promptly induced an unquenchable apoptotic process selectively in tumor cells, with mitochondrial and lysosomal involvement. Altogether, these results demonstrate that the most active compound acts as a promising singlet oxygen sensitizer for biological applications.
Collapse
|
10
|
Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W. Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. J Med Chem 2018. [PMID: 29522671 DOI: 10.1021/acs.jmedchem.7b01843] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Fibroblast growth factor receptors (FGFR1-4) are promising therapeutic targets in many cancers. With the resurgence of interest in irreversible inhibitors, efforts have been directed to the discovery of irreversible FGFR inhibitors. Currently, several selective irreversible inhibitors are being evaluated in clinical trials that could covalently target a conserved cysteine in the P-loop of FGFR. In this article, we used a structure-guided approach that is rationalized by a computer-aided simulation to discover the novel and irreversible pan-FGFR inhibitor, 9g, which provided superior FGFR in vitro activities and decent selectivity over VEGFR2 (vascular endothelia growth factor receptor 2). In in vivo studies, 9g displayed clear antitumor activities in NCI-H1581 and SNU-16 xenograft mice models. Additionally, the diluting method confirmed the irreversible binding of 9g to FGFR.
Collapse
Affiliation(s)
- Yuming Wang
- Department of Medicinal Chemistry , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Lijun Li
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Jun Fan
- Department of Medicinal Chemistry , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Yang Dai
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Alan Jiang
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Meiyu Geng
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Jing Ai
- Division of Antitumor Pharmacology, State Key Laboratory of Drug Research , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| | - Wenhu Duan
- Department of Medicinal Chemistry , Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences , 555 Zu Chong Zhi Road , Shanghai 201203 , P. R. China.,University of Chinese Academy of Sciences , No.19A Yuquan Road , Beijing 100049 , P. R. China
| |
Collapse
|
11
|
Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J, Loughhead DG, Ton T, Karr DE, Gerritsen ME, Goldstein DM, Funk JO. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. J Med Chem 2017; 60:6516-6527. [DOI: 10.1021/acs.jmedchem.7b00360] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Ken A. Brameld
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Timothy D. Owens
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Erik Verner
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Eleni Venetsanakos
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - J. Michael Bradshaw
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Vernon T. Phan
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Danny Tam
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Kwan Leung
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Jin Shu
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Jacob LaStant
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - David G. Loughhead
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Tony Ton
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Dane E. Karr
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Mary E. Gerritsen
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - David M. Goldstein
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| | - Jens Oliver Funk
- Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States
| |
Collapse
|
12
|
Naeimi H, Didar A. Facile one-pot four component synthesis of pyrido[2,3-d:6,5-d′]dipyrimidines catalyzed by CuFe 2 O 4 magnetic nanoparticles in water. J Mol Struct 2017. [DOI: 10.1016/j.molstruc.2017.02.044] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Sonochemical synthesis of pyrido[2,3-d:6,5-d′]-dipyrimidines catalyzed by [HNMP]+[HSO4]− and their antimicrobial activity studies. J Antibiot (Tokyo) 2017; 70:845-852. [DOI: 10.1038/ja.2017.47] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 01/24/2017] [Accepted: 02/23/2017] [Indexed: 11/08/2022]
|
14
|
Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models. Mol Cancer Ther 2016; 15:2630-2639. [DOI: 10.1158/1535-7163.mct-16-0261] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 08/04/2016] [Indexed: 11/16/2022]
|
15
|
Yan W, Wang X, Dai Y, Zhao B, Yang X, Fan J, Gao Y, Meng F, Wang Y, Luo C, Ai J, Geng M, Duan W. Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation. J Med Chem 2016; 59:6690-708. [PMID: 27348537 DOI: 10.1021/acs.jmedchem.6b00056] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Fibroblast growth factor receptor (FGFR) represents an attractive oncology target for cancer therapy in view of its critical role in promoting cancer formation and progression, as well as causing resistance to approved therapies. In this article, we describe the identification of the potent pan-FGFR inhibitor (R)-21c (FGFR1-4 IC50 values of 0.9, 2.0, 2.0, and 6.1 nM, respectively). Compound (R)-21c exhibited excellent in vitro inhibitory activity against a panel of FGFR-amplified cell lines. Western blot analysis demonstrated that (R)-21c suppressed FGF/FGFR and downstream signaling pathways at nanomolar concentrations. Moreover, (R)-21c provided nearly complete inhibition of tumor growth (96.9% TGI) in NCI-H1581 (FGFR1-amplified) xenograft mice model at the dose of 10 mg/kg/qd via oral administration.
Collapse
Affiliation(s)
- Wei Yan
- School of Pharmacy, East China University of Science & Technology , 130 Mei Long Road, Shanghai 200237, P. R. China
| | - Xinyi Wang
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China.,University of Chinese Academy of Sciences , Beijing 100049, P. R. China
| | - Yang Dai
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Bin Zhao
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Xinying Yang
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Jun Fan
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Yinglei Gao
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Fanwang Meng
- Department of Chemistry, College of Sciences, Shanghai University , 99 Shang Da Road, Shanghai 200444, P. R. China.,Drug Discovery & Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Yuming Wang
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Cheng Luo
- Drug Discovery & Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Jing Ai
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Meiyu Geng
- Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Wenhu Duan
- School of Pharmacy, East China University of Science & Technology , 130 Mei Long Road, Shanghai 200237, P. R. China.,Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| |
Collapse
|
16
|
Zhou N, Xu Y, Liu X, Wang Y, Peng J, Luo X, Zheng M, Chen K, Jiang H. Combinatorial Pharmacophore-Based 3D-QSAR Analysis and Virtual Screening of FGFR1 Inhibitors. Int J Mol Sci 2015; 16:13407-26. [PMID: 26110383 PMCID: PMC4490501 DOI: 10.3390/ijms160613407] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Revised: 06/01/2015] [Accepted: 06/01/2015] [Indexed: 12/22/2022] Open
Abstract
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays crucial roles in cell proliferation, angiogenesis, migration, and survival. Aberration in FGFRs correlates with several malignancies and disorders. FGFRs have proved to be attractive targets for therapeutic intervention in cancer, and it is of high interest to find FGFR inhibitors with novel scaffolds. In this study, a combinatorial three-dimensional quantitative structure-activity relationship (3D-QSAR) model was developed based on previously reported FGFR1 inhibitors with diverse structural skeletons. This model was evaluated for its prediction performance on a diverse test set containing 232 FGFR inhibitors, and it yielded a SD value of 0.75 pIC50 units from measured inhibition affinities and a Pearson’s correlation coefficient R2 of 0.53. This result suggests that the combinatorial 3D-QSAR model could be used to search for new FGFR1 hit structures and predict their potential activity. To further evaluate the performance of the model, a decoy set validation was used to measure the efficiency of the model by calculating EF (enrichment factor). Based on the combinatorial pharmacophore model, a virtual screening against SPECS database was performed. Nineteen novel active compounds were successfully identified, which provide new chemical starting points for further structural optimization of FGFR1 inhibitors.
Collapse
Affiliation(s)
- Nannan Zhou
- State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of Chemical Bilolgy, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
| | - Yuan Xu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Xian Liu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Yulan Wang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Jianlong Peng
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Xiaomin Luo
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Mingyue Zheng
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Kaixian Chen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | - Hualiang Jiang
- State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of Chemical Bilolgy, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| |
Collapse
|
17
|
Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs. Bioorg Med Chem Lett 2015; 25:1556-60. [DOI: 10.1016/j.bmcl.2015.02.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 02/02/2015] [Accepted: 02/06/2015] [Indexed: 01/20/2023]
|
18
|
Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, Bifulco N, Kim JL, Hodous B, Brooijmans N, Shutes A, Winter C, Lengauer C, Kohl NE, Guzi T. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov 2015; 5:424-37. [PMID: 25776529 DOI: 10.1158/2159-8290.cd-14-1029] [Citation(s) in RCA: 233] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 02/03/2015] [Indexed: 11/16/2022]
Abstract
UNLABELLED Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans. We have developed BLU9931, a potent and irreversible small-molecule inhibitor of FGFR4, as a targeted therapy to treat patients with HCC whose tumors have an activated FGFR4 signaling pathway. BLU9931 is exquisitely selective for FGFR4 versus other FGFR family members and all other kinases. BLU9931 shows remarkable antitumor activity in mice bearing an HCC tumor xenograft that overexpresses FGF19 due to amplification as well as a liver tumor xenograft that overexpresses FGF19 mRNA but lacks FGF19 amplification. Approximately one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor. These findings are the first demonstration of a therapeutic strategy that targets a subset of patients with HCC. SIGNIFICANCE This article documents the discovery of BLU9931, a novel irreversible kinase inhibitor that specifically targets FGFR4 while sparing all other FGFR paralogs and demonstrates exquisite kinome selectivity. BLU9931 is efficacious in tumors with an intact FGFR4 signaling pathway that includes FGF19, FGFR4, and KLB. BLU9931 is the first FGFR4-selective molecule for the treatment of patients with HCC with aberrant FGFR4 signaling.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antineoplastic Agents/chemistry
- Antineoplastic Agents/pharmacology
- Carcinoma, Hepatocellular/drug therapy
- Carcinoma, Hepatocellular/metabolism
- Carcinoma, Hepatocellular/pathology
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Disease Models, Animal
- Humans
- Liver Neoplasms/drug therapy
- Liver Neoplasms/metabolism
- Liver Neoplasms/pathology
- Mice
- Models, Molecular
- Molecular Conformation
- Molecular Sequence Data
- Protein Binding
- Protein Kinase Inhibitors/chemistry
- Protein Kinase Inhibitors/pharmacology
- Receptor, Fibroblast Growth Factor, Type 4/antagonists & inhibitors
- Receptor, Fibroblast Growth Factor, Type 4/chemistry
- Receptor, Fibroblast Growth Factor, Type 4/metabolism
- Sequence Alignment
- Signal Transduction/drug effects
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
| | | | | | | | - Weifan Weng
- Blueprint Medicines, Cambridge, Massachusetts
| | | | | | | | | | | | - Adam Shutes
- Blueprint Medicines, Cambridge, Massachusetts
| | | | | | | | | |
Collapse
|
19
|
Ye F, Wang Y, Nian S, Wang Y, Chen D, Yu S, Wang S. Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1. J Enzyme Inhib Med Chem 2015; 30:961-6. [PMID: 25683078 DOI: 10.3109/14756366.2014.1002401] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
A series of 5,7-dimethyl-oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives, N5a-5l, was designed, synthesized and evaluated for their FGFR1-inhibition ability as well as cytotoxicity against three cancer cell lines (H460, B16F10 and A549) in vitro. Several compounds displayed good-to-excellent potency against these cancer cell lines compared to SU5402. Structure-activity relationship analyses indicated that compounds with a rigid structure and more heteroatoms at the side chain of the parent ring were more effective than those without these substitutions. The compound N5g (37.4% FGFR1 inhibition at 1.0 μM) was identified to have the most potent antitumor activities, with IC50 values of 5.472, 4.260 and 5.837 μM against H460, B16F10 and A549 cell lines, respectively. Together, our results suggest that 5,7-dimethyl-oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives may serve as potential agents for the treatment of FGFR1-mediated cancers.
Collapse
Affiliation(s)
- Faqing Ye
- a School of Pharmacy, Health Science Center Xi'an Jiaotong University , Xi'an , China and.,b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Yuewu Wang
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Siyun Nian
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Yu Wang
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Di Chen
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Shufang Yu
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Sicen Wang
- a School of Pharmacy, Health Science Center Xi'an Jiaotong University , Xi'an , China and
| |
Collapse
|
20
|
Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov Today 2013; 19:51-62. [PMID: 23932951 DOI: 10.1016/j.drudis.2013.07.021] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 07/23/2013] [Accepted: 07/30/2013] [Indexed: 01/23/2023]
Abstract
Aberrations in fibroblast growth factor receptor (FGFR) signaling are instrumental to the pathophysiology of several malignancies and disorders. Hence, FGFR inhibitors are explored in therapeutics with early candidates developed as competitors for the ATP-binding pocket in the kinase domain. More recent programs yielded compounds of diverse scaffolds with alternative binding modes. Concurrently, monoclonal antibodies and peptide-based agents provide independent options for clinical development. Notwithstanding this rapid progress, we contemplate the toxicological impact of FGFR inhibition based on the defined role of FGFR family members in physiology and homeostasis. The high homology among FGFR1-4 and also with other kinase subfamilies creates an additional challenge in developing selective inhibitors. It orchestrates an ongoing conundrum of moderating a balance between synergism through multitargeting kinase inhibition and minimizing off-target toxicities.
Collapse
|
21
|
Bennett EL, Black GP, Browne P, Hizi A, Jaffar M, Leyland JP, Martin C, Oz-Gleenberg I, Murphy PJ, Roberts TD, Thornhill AJ, Vale SA. Synthesis and biological activity of analogues of batzelladine F. Tetrahedron 2013. [DOI: 10.1016/j.tet.2013.01.083] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
22
|
Lorente A, Lamariano-Merketegi J, Albericio F, Álvarez M. Tetrahydrofuran-containing macrolides: a fascinating gift from the deep sea. Chem Rev 2013; 113:4567-610. [PMID: 23506053 DOI: 10.1021/cr3004778] [Citation(s) in RCA: 250] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Adriana Lorente
- Institute for Research in Biomedicine, Barcelona Science Park, University of Barcelona, Baldiri Reixac 10, 08028 Barcelona, Spain
| | | | | | | |
Collapse
|
23
|
Gurupadaswamy HD, Girish V, Kavitha CV, Raghavan SC, Khanum SA. Synthesis and evaluation of 2,5-di(4-aryloylaryloxymethyl)-1,3,4-oxadiazoles as anti-cancer agents. Eur J Med Chem 2013; 63:536-43. [PMID: 23535322 DOI: 10.1016/j.ejmech.2013.02.040] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2012] [Revised: 01/21/2013] [Accepted: 02/28/2013] [Indexed: 11/16/2022]
Abstract
A series of 2,5-di(4-aryloylaryloxymethyl)-1,3,4-oxadiazoles 9a-j were obtained via multistep synthesis from hydroxybenzophenones 4a-e. The cytotoxicity of compounds 9a-j was evaluated against human leukemia cell lines (K562 and CEM). The compounds exhibited moderate to good anti-cancer activity with compounds 9b and 9i having a chloro group exhibiting the best activity (IC50 = 10 μM). Compound 9i exhibited activity against both the cell lines and 9b only exhibited activity against CEM. Further, a lactate dehydrogenase (LDH) assay and DNA fragmentation studies of the compounds 9a-j were also performed.
Collapse
Affiliation(s)
- H D Gurupadaswamy
- Department of Chemistry, Yuvaraja's College Mysore, University of Mysore, Mysore 570 006, India
| | | | | | | | | |
Collapse
|
24
|
Wang Y, Xu ZL, Ai J, Peng X, Lin JP, Ji YC, Geng MY, Long YQ. Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors. Org Biomol Chem 2013. [DOI: 10.1039/c2ob26710a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
25
|
Iaroshenko VO, Vilches-Herrera M, Gevorgyan A, Mkrtchyan S, Arakelyan K, Ostrovskyi D, Abbasi MS, Supe L, Hakobyan A, Villinger A, Volochnyuk DM, Tolmachev A. Design, synthesis and transformation of some heteroannulated 3-aminopyridines—purine isosteres with exocyclic nitrogen atom. Tetrahedron 2013. [DOI: 10.1016/j.tet.2012.11.026] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
26
|
Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties. J Med Chem 2012; 55:9492-509. [DOI: 10.1021/jm300667v] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Li-Fan Zeng
- State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | - Yong Wang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | - Roza Kazemi
- Department of Pharmacology and Pharmaceutical
Sciences, School of Pharmacy, University of Southern California, 1985
Zonal Avenue, Los Angeles, California 90089, United States
| | - Shili Xu
- Department of Pharmacology and Pharmaceutical
Sciences, School of Pharmacy, University of Southern California, 1985
Zonal Avenue, Los Angeles, California 90089, United States
| | - Zhong-Liang Xu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | - Tino W. Sanchez
- Department of Pharmacology and Pharmaceutical
Sciences, School of Pharmacy, University of Southern California, 1985
Zonal Avenue, Los Angeles, California 90089, United States
| | - Liu-Meng Yang
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming
Institute of Zoology, Chinese Academy of Sciences, Kunming 650223,
China
| | - Bikash Debnath
- Department of Pharmacology and Pharmaceutical
Sciences, School of Pharmacy, University of Southern California, 1985
Zonal Avenue, Los Angeles, California 90089, United States
| | - Srinivas Odde
- Department of Pharmacology and Pharmaceutical
Sciences, School of Pharmacy, University of Southern California, 1985
Zonal Avenue, Los Angeles, California 90089, United States
| | - Hua Xie
- State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | - Yong-Tang Zheng
- Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming
Institute of Zoology, Chinese Academy of Sciences, Kunming 650223,
China
| | - Jian Ding
- State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | - Nouri Neamati
- Department of Pharmacology and Pharmaceutical
Sciences, School of Pharmacy, University of Southern California, 1985
Zonal Avenue, Los Angeles, California 90089, United States
| | - Ya-Qiu Long
- State Key Laboratory of Drug Research, Shanghai Institute of Materia
Medica, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| |
Collapse
|
27
|
Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33:531-41. [PMID: 22884522 DOI: 10.1016/j.tips.2012.07.001] [Citation(s) in RCA: 94] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2012] [Revised: 06/28/2012] [Accepted: 07/10/2012] [Indexed: 01/25/2023]
Abstract
The fibroblast growth factor receptor (FGFR) family includes four highly conserved receptor tyrosine kinases: FGFR1-4. Upon ligand binding, FGFRs activate an array of downstream signaling pathways, such as the mitogen activated protein kinase (MAPK) and the phosphoinositide-3-kinase (PI3K)/Akt pathways. These FGFR cascades play crucial roles in tumor cell proliferation, angiogenesis, migration, and survival. The combination of knockdown studies and pharmaceutical inhibition in preclinical models demonstrates that FGFRs are attractive targets for therapeutic intervention in cancer. Multiple FGFR inhibitors with various structural skeletons have been designed, synthesized, and evaluated. Reviews on FGFRs have recently focused on FGFR signaling, pathophysiology, and functions in cancer or other diseases. In this article, we review recent advances in structure-activity relationships (SAR) of FGFR inhibitors, as well as the FGFR-targeting drug design strategies currently employed in targeting deregulated FGFRs by antibodies and small molecule inhibitors.
Collapse
Affiliation(s)
- Guang Liang
- School of Pharmaceutical Sciences, Wenzhou Medical College, Wenzhou 325035, China.
| | | | | | | | | |
Collapse
|
28
|
Norman RA, Schott AK, Andrews DM, Breed J, Foote KM, Garner AP, Ogg D, Orme JP, Pink JH, Roberts K, Rudge DA, Thomas AP, Leach AG. Protein–Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase. J Med Chem 2012; 55:5003-12. [DOI: 10.1021/jm3004043] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Richard A. Norman
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Anne-Kathrin Schott
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - David M. Andrews
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Jason Breed
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Kevin M. Foote
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Andrew P. Garner
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Derek Ogg
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Jonathon P. Orme
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Jennifer H. Pink
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Karen Roberts
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - David A. Rudge
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Andrew P. Thomas
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| | - Andrew G. Leach
- AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K
| |
Collapse
|
29
|
Synthesis of heteroannulated 3-nitro- and 3-aminopyridines by cyclocondensation of electron-rich aminoheterocycles with 3-nitrochromone. Tetrahedron 2012. [DOI: 10.1016/j.tet.2011.06.101] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H, Wartmann M, Berghausen J, Drueckes P, Zimmerlin A, Bussiere D, Murray J, Graus Porta D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54:7066-83. [PMID: 21936542 DOI: 10.1021/jm2006222] [Citation(s) in RCA: 365] [Impact Index Per Article: 28.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.
Collapse
Affiliation(s)
- Vito Guagnano
- Novartis Institute for BioMedical Research, CH-4002 Basel, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
3-Acylindoles as versatile starting materials for pyridine ring annulation: synthesis of 1-deazapurine isosteres. Tetrahedron 2011. [DOI: 10.1016/j.tet.2011.05.037] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
32
|
Barillari C, Duncan AL, Westwood IM, Blagg J, van Montfort RLM. Analysis of water patterns in protein kinase binding sites. Proteins 2011; 79:2109-21. [PMID: 21557316 DOI: 10.1002/prot.23032] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2010] [Revised: 03/02/2011] [Accepted: 03/03/2011] [Indexed: 11/10/2022]
Abstract
Deregulation of protein kinases is associated with numerous diseases, making them important targets for drug discovery. The majority of drugs target the catalytic site of these proteins, but due to the high level of similarity within the ATP binding sites of protein kinases, it is often difficult to achieve the required pharmacological selectivity. In this study, we describe the identification and subsequent analysis of water patterns in the ATP binding sites of 171 protein kinase structures, comprising 19 different kinases from various branches of the kinome, and demonstrate that structurally similar binding sites often have significantly different water patterns. We show that the observed variations in water patterns of different, but structurally similar kinases can be exploited in the structure-based design of potent and selective kinase inhibitors.
Collapse
Affiliation(s)
- Caterina Barillari
- Section of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, United Kingdom
| | | | | | | | | |
Collapse
|
33
|
Synthesis and structure–activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors. Bioorg Med Chem 2010; 18:4674-86. [DOI: 10.1016/j.bmc.2010.05.021] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2010] [Revised: 05/05/2010] [Accepted: 05/06/2010] [Indexed: 01/08/2023]
|
34
|
Prasanna DS, Kavitha CV, Vinaya K, Ranganatha SR, Raghava B, Kumar YCS, Raghavan SC, Rangappa KS. Synthesis and Antileukemic Activity of 1-((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-3-(substituted phenyl)urea Derivatives. BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN 2010. [DOI: 10.1246/bcsj.20090318] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
35
|
Mkrtchyan S, Iaroshenko VO, Dudkin S, Gevorgyan A, Vilches-Herrera M, Ghazaryan G, Volochnyuk DM, Ostrovskyi D, Ahmed Z, Villinger A, Sosnovskikh VY, Langer P. 3-Methoxalylchromone—a novel versatile reagent for the regioselective purine isostere synthesis. Org Biomol Chem 2010; 8:5280-4. [DOI: 10.1039/c0ob00379d] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
36
|
Le Corre L, Girard AL, Aubertin J, Radvanyi F, Benoist-Lasselin C, Jonquoy A, Mugniery E, Legeai-Mallet L, Busca P, Le Merrer Y. Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors. Org Biomol Chem 2010; 8:2164-73. [DOI: 10.1039/b923882d] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
37
|
Niu J, Guo P, Kang J, Li Z, Xu J, Hu S. Copper(I)-Catalyzed Aryl Bromides To Form Intermolecular and Intramolecular Carbon−Oxygen Bonds. J Org Chem 2009; 74:5075-8. [DOI: 10.1021/jo900600m] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jiajia Niu
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, Graduate School of Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, and Institute for Diabetes Discovery, Branford, Connecticut 06405
| | - Pengran Guo
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, Graduate School of Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, and Institute for Diabetes Discovery, Branford, Connecticut 06405
| | - Juntao Kang
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, Graduate School of Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, and Institute for Diabetes Discovery, Branford, Connecticut 06405
| | - Zhigang Li
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, Graduate School of Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, and Institute for Diabetes Discovery, Branford, Connecticut 06405
| | - Jingwei Xu
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, Graduate School of Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, and Institute for Diabetes Discovery, Branford, Connecticut 06405
| | - Shaojing Hu
- State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, Graduate School of Chinese Academy of Sciences, Changchun 130022, People’s Republic of China, and Institute for Diabetes Discovery, Branford, Connecticut 06405
| |
Collapse
|
38
|
Affiliation(s)
- J. S. Yadav
- Organic Chemistry Division I, Indian Institute of Chemical Technology, Hyderabad 500607, India
| | - Ch. Suresh Reddy
- Organic Chemistry Division I, Indian Institute of Chemical Technology, Hyderabad 500607, India
| |
Collapse
|
39
|
Li J, Qin J, Liu H, Yao X, Liu M, Hu Z. In Silico Prediction of Inhibition Activity of Pyrazine–Pyridine Biheteroaryls as VEGFR-2 Inhibitors Based on Least Squares Support Vector Machines. ACTA ACUST UNITED AC 2008. [DOI: 10.1002/qsar.200630154] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
40
|
Gregg BT, Golden KC, Quinn JF, Tymoshenko DO, Earley WG, Maynard DA, Razzano DA, Rennells WM, Butcher J. Expedient Lewis Acid Catalyzed Synthesis of a 3-Substituted 5-Arylidene-1-methyl-2-thiohydantoin Library. ACTA ACUST UNITED AC 2007; 9:1036-40. [PMID: 17867645 DOI: 10.1021/cc700103u] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An efficient and rapid solution phase combinatorial synthesis of a 3-substituted 5-arylidene-1-methyl-2-thiohydantoin library was developed. The salient feature for this library production procedure is the addition of the Lewis acid catalyst, indium(III) trifluoromethanesulfonate, which serves to facilitate the direct condensation of aldehydes with 3-substituted 1-methyl-2-thiohydantoins. Use of this Lewis acid catalyst has resulted in faster reaction times, higher conversions and better purity profiles for these condensation reactions as compared to traditional uncatalyzed reactions. The resulting 315 member library of 3-substituted 5-arylidene-1-methyl-2-thiohydantoin is described.
Collapse
Affiliation(s)
- Brian T Gregg
- Department of Medical Chemistry, AMRI, 26 Corporate Circle, Albany, New York 12203, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Xie Y, Mo W, Xu D, Shen Z, Sun N, Hu B, Hu X. Efficient NO Equivalent for Activation of Molecular Oxygen and Its Applications in Transition-Metal-Free Catalytic Aerobic Alcohol Oxidation. J Org Chem 2007; 72:4288-91. [PMID: 17447820 DOI: 10.1021/jo0705824] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
tert-Butyl nitrite (TBN) was identified as an efficient NO equivalent for the activation of molecular oxygen. The unique property of TBN enabled TEMPO-catalyzed aerobic alcohol oxidation to be performed in high-volume efficiency. Up to a 16,000 turnover number was achieved in this transition-metal-free aerobic catalytic system. Under the optimal reaction conditions, various alcohols were converted into their corresponding carbonyl compounds with TEMPO/HBr/TBN as catalyst. The newly developed method was suitable for the oxidation of solid substrate alcohols with high melting point and/or low solubility under the help of minimum solvent to form a slurry.
Collapse
Affiliation(s)
- Yi Xie
- College of Chemical Engineering and Material Sciences, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China
| | | | | | | | | | | | | |
Collapse
|